分析特拉唑嗪联合爱普列特治疗良性前列腺增生的临床效果

Shallow of Terazosin Joint Epristeride Clinical Effect for the Treatment of Benign Prostatic Hyperplasia

目的探究联合应用特拉唑嗪和爱普列特治疗良性前列腺增生的临床效果。方法选择2015年2月—2016年1月于该院就诊的122例良性前列腺增生患者,应用随机数字表法将所有患者分为两组,实验组60例,应用特拉唑前联合爱普列特进行治疗,对照组62例应用特拉唑嗪进行治疗,比较两组患者治疗前后的前列腺体积、残余尿量、最大尿流率以及症状评分情况,并进行为期6个月的随访,记录不良反应情况。结果治疗前,实验组与对照组的前列腺体积、残余尿量、最大尿流率以及症状评分等指标差异无统计学意义;治疗后,两组患者的各项指标均有所改善,实验组前列腺体积、残余尿量、最大尿流率以及症状评分分别为(31.7±10.4)cm^3、(30.4±18.5)mL、(17.2±4.8)mL/s和(10.8±5.1)分,对照组分别为(35.6±11.2)cm^3、(38.3±19.1)mL、(13.3±3.7)mL/s和(14.7±4.5)分,两组相比差异有统计学意义(P<0.05),随访中,实验组不良情况发生率为11.67%,对照组为10.00%,两组相比差异无统计学意义(P>0.05)。结论在良性前列腺增生的治疗过程中,应用特拉唑嗪联合爱普列特进行治疗临床效果显著,适合在临床上推广。

Objective To explore the combined use of terazosin and epristeride clinical effect for the treatment of be-nign prostatic hyperplasia. Methods Choose February 2015 to January 2016 clinic in our hospital between January of 122 patients with benign prostatic hyperplasia, random number table method was applied to all patients were divided into two groups, experimental group has 60 cases, applied terra azole treatment before united＇s epristeride, and the con-trol group has 62 cases, used terazosin treatment, compared two groups of patients before and after treatment of prostate volume, residual urine volume, maximum urine flow rate and symptom scores, and for a period of 6 months follow-up, record adverse reactions. Results Before treatment, the experimental group and control group of prostate volume, resid-ual urine volume, maximum urine flow rate, and no difference between the indexes of symptom scores. After treatment, the indicators of two groups of patients were improved, in experimental the prostate volume、 residual urine volume、maximum urine flow rate and the symptom scores were （31.7±10.4）cm3、（30.4±18.5）mL、（17.2±4.8）mL/s、（10.8±5.1） score,and in the control group were （35.6±11.2）cm3、（38.3±19.1）mL、（13.3±3.7）mL/s、（14.7±4.5）score.Compared two groups of significant difference （P〈 0.05）.In the follow-up visiting, in the experimental group there were 11.67% Ad-verse events happened, however,the control group were 10.00% Adverse events happened, compared two groups had no statistical difference （P〉 0.05）. Conclusion In the process of the treatment of benign prostatic hyperplasia, the appli-cation of combined love terazosin presidio treatment clinical effect is remarkable, suitable for clinical promotion.